Skip to main content
  • Poster presentation
  • Open access
  • Published:

A new intranasal therapy (MP29-02*) is more effective than current firstline therapy regardless of season, symptom or severity.


Moderate-to-severe allergic rhinitis (AR) is often poorly controlled. Patients remain symptomatic on treatment, despite multiple therapies. A more effective treatment is needed. We assessed the efficacy of MP29-02* (a novel intranasal formulation of azelastine hydrochloride (AZE) and fluticasone propionate (FP) in an advanced delivery system) during different seasons and for different symptoms and severities vs AZE, FP or placebo (PLA).


Four thousand and twenty two moderate/severe SAR patients (≥12 yrs) were randomized into 4 double-blind, PLA-controlled, 14-day, parallel-group trials to MP29-02*, AZE, FP or PLA nasal sprays (1 spray/nostril bid), during the Texas mountain cedar (MP4001), Spring (MP4002), Autumn (MP4004) and Spring/Summer (MP4006) seasons. Overall change from baseline (CFB) in reflective total nasal symptom score (rTNSS) was the primary endpoint. It was assessed by severity post-hoc in 2 ways (more severe AR: median baseline rTNSS >18.9 or median baseline RQLQ >3.9; less severe AR: median baseline rTNSS ≤18.9 or median baseline RQLQ ≤ 3.9). CFB in individual nasal and ocular symptom scores was also assessed.


The response to MP29-02* was consistent across seasons; mean CFB -5.5, -5.5, -5.6 and -5.6 in each study (p<0.001 vs PLA). Nasal symptom relief was significantly greater with MP29-02* than with FP or AZE in all studies. In study MP4001 MP29-02 was approx. twice as effective as FP (relative difference (RD) 47%; p=0.0031) and 3 times as effective as AZE (RD: 66%; p<0.0001). For less severe AR (defined by median baseline rTNSS) the RD to MP29-02* was 42% vs FP (p=0.0188) and 64% vs AZE (p=0.0002), increasing to 49% and 70% vs FP (p=0.0436) and AZE (p=0.0035), respectively for more severe AR. When severity was categorized according to median baseline RQLQ the RD to MP29-02* was 60% vs FP (p=0.0244) and 69% vs AZE (p=0.0068) for those with less severe AR compared to 49% vs FP (p=0.0194) and 64% vs AZE (p=0.0013) for those with more severe AR. MP29-02* provided superior relief from all nasal and ocular symptoms than AZE or FP, which was particularly evident for congestion (p=0.0034 vs FP; p=0.0001 vs AZE) & ocular itching (p=0.0240 vs FP; p=0.0033 vs AZE).


MP29-02* provides consistently superior symptomatic relief to an intranasal antihistamine or topical corticosteroid in AR patients regardless of season, symptom or severity, supporting MP29-02 as the drug of choice for AR.


Author information

Authors and Affiliations


Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bachert, C., Fokkens, W., Hellings, P. et al. A new intranasal therapy (MP29-02*) is more effective than current firstline therapy regardless of season, symptom or severity.. Clin Transl Allergy 5 (Suppl 4), P38 (2015).

Download citation

  • Published:

  • DOI: